Shareholders of Neimeth International Pharmaceuticals Plc have approved a major capital restructuring scheme that will reduce the company’s share premium account from N2.38 billion to N390.02 million and transfer N1.99 billion to its retained earnings reserve.

Nairametrics reported that the approval was granted at a Court-Ordered Meeting held virtually, where shareholders backed up the Scheme of Arrangement aimed at strengthening the company’s balance sheet and enhancing financial flexibility for future operations.

The restructuring forms part of Neimeth’s broader corporate reorganisation efforts as the pharmaceutical firm seeks to improve its capital structure and position itself for long-term growth.

The approved scheme represents a balance sheet restructuring exercise rather than an injection of new capital into the company.

The Scheme of Arrangement was detailed in the company’s Scheme Document dated February 25, 2026.

Under the arrangement, Neimeth will reduce its share premium account by N1.99 billion, bringing the balance down to N390.02 million, while transferring the same amount into retained earnings, also known as revenue reserves.

Share premium refers to funds paid by investors above the nominal value of a company’s shares.

Although it forms part of shareholders’ equity, it is typically subject to regulatory restrictions and cannot be freely utilised for dividends or certain operational adjustments.

Retained earnings, on the other hand, provide greater financial flexibility and can be applied toward offsetting accumulated losses, supporting future dividend payments, or strengthening reserves.

The move is widely regarded as a capital structure optimization strategy aimed at unlocking trapped reserves within the company’s equity base without altering total shareholders’ funds.

Analysts say the restructuring could improve Neimeth’s financial presentation and strengthen its ability to pursue future growth initiatives.

By transferring N1.99 billion into retained earnings, the company gains more usable reserves that may support future balance sheet adjustments and improve investor perception of its financial health.

The restructuring creates room for future dividend declarations if the company returns to sustained profitability, while potentially enhancing its attractiveness to lenders and investors.

Despite the adjustment, the exercise does not introduce fresh cash into the business and will not immediately impact the company’s operating cash flow or earnings performance.

Instead, it represents an internal reclassification of equity designed to provide greater flexibility in capital management and improve the structure of the company’s reserves.

Shareholders also authorised the Board of Directors to implement the Scheme of Arrangement in full and approve any modifications required by the Securities and Exchange Commission (SEC) or the Court.

In addition, the company’s solicitors were mandated to seek court sanctions for the scheme and obtain all incidental orders necessary to give legal effect to the restructuring.

Corporate restructuring exercises involving share premium reductions are commonly deployed by companies seeking to optimise their balance sheets, improve reserve flexibility, and strengthen long-term financial positioning without issuing new shares or raising additional capital.

Neimeth first disclosed plans for the restructuring in February 2026, when it announced a Court-Ordered Meeting to seek shareholders’ approval for the proposed transfer of N1.99 billion from its share premium account into retained earnings reserves.

The pharmaceutical company explained at the time that the move was designed to reorganise its equity structure in line with applicable regulatory provisions.
It was also meant to create a more efficient reserve base for future corporate actions and business expansion initiatives, according to the company.

Analysts note that it could enhance Neimeth’s financial presentation, support future dividend flexibility, and improve its ability to attract investors and financing over the long term.
The restructuring remains subject to final regulatory and court approvals before it can be fully implemented.